American college of endocrinology pre-diabetes consensus conference: Part three

Diabetes Care

Volumn 31, Issue 12, 2008, Pages 2404-2409

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CALCIFEDIOL; GLITAZONE DERIVATIVE; GLUCOSE; GLUCOSE 6 PHOSPHATE; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LIPID; METFORMIN; PROSTAGLANDIN F2 ALPHA; TRIACYLGLYCEROL;

ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CONSENSUS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; EVIDENCE BASED PRACTICE; FATTY ACID TRANSPORT; GENETIC SUSCEPTIBILITY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MEDICAL SOCIETY; METABOLIC SYNDROME X; MICROANGIOPATHY; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PATHOGENESIS; PATIENT MONITORING; POPULATION RISK; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

HUMANS; PREDIABETIC STATE;

EID: 64349124464     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-zb12     Document Type: Article

References (57)

1. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE: Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 46:1594-1600, 1997
2. Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE: Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study. AnnlnternMed 128:524-533, 1998
3. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, Nesto RW, WilsonPW, Vasan RS: Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107:448-454, 2003
4. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112: 3066-3072, 2005
5. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB Sr, Wilson PW: Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 30:1219-1225, 2007
6. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr: Prediction of incident diabetes mellitus in middle- aged adults: the Framingham Offspring Study. Arch Intern Med 167:1068-1074, 2007
7. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263:2893-2898,1990
8. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 101:975-980, 2000
9. Festa A, D'Agostino RJr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (insulin resistanceAS). Circulation 102:42-47, 2000
10. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute- phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51:1131-1137, 2002
11. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM: The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26:3153-3159, 2003
12. Hanley AJ, Williams K, Festa A, Wagen- knecht LE, D'Agostino RB Jr, Haffner SM: Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54: 3140-3147, 2005
13. Nichols GA, Hillier TA, Brown JB: Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diabetes Care 30:228-233, 2007
14. Woerle HJ, Pimenta WP, Meyer C, Gosmanov NR, Szoke E, Szombathy T, Mitrakou A, Gerich JE: Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values. Arch Intern Med 164:1627-1632, 2004
15. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, Heine RJ: Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetolo- gia 39:298-305, 1996
16. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, the A1c-Derived Average Glucose (ADAG) Study Group: Translating the A1C assay into estimated average glucose values. Diabetes Care 31: 1473-1478, 2008
17. Saudek CD, Herman WH, Sacks DB, Ber- genstal RM, Edelman D, Davidson MB: A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 93:2447-2453, 2008
18. Schwedes U, Siebolds M, Mertes G, the SMBG Study Group: Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin- treated type 2 diabetic patients. Diabetes Care 25:1928-1932, 2002
19. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ: Baseline serum 25-hy- droxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely prospective study 1990-2000. Diabetes 57:2619-2625, 2008
20. Knekt P, Laaksonen M, Mattila C, Har- kanen T, Marniemi J, Heliovaara M, Ris- sanen H, Montonen J, Reunanen A: Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 20 May 2008 [Epub ahead of print]
21. Martins D, Wolf M, Pan D, Zadshir A, Ta- reen N, Thadhani R, Felsenfeld A, Levine B, Mehrotra R, Norris K: Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 167:1159-1165, 2007
22. Quagliaro L, Piconi L, Assaloni R, Marti- nelli L, Motz E, Ceriello A: Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52:2795-2804, 2003
23. Ceriello A, Bortolotti N, Motz E, Pieri C, Marra M, Tonutti L, Lizzio S, Feletto F, Catone B, Taboga C: Meal-induced oxida- tive stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 48:1503-1508, 1999
24. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681-1687, 2006
25. Brownlee M, Hirsch IB: Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 295:1707-1708, 2006
26. 1c as markers of diabetic complications. Diabetes 48:870 -880, 199927. American Diabetes Association: Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31:596 -615, 2008
27. Caro JJ, Ward AJ, O'Brien JA: Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 25: 476 -481, 2002
28. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group: The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142:323-332, 2005
29. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG: Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin- dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl JMed 322:223-228, 1990
30. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, Inzucchi S, Dresner A, Rothman DL, Shulman GI: Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl JMed 341:240-246, 1999
31. Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, Ro- den M, Shulman GI: Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42:113-116, 1999
32. Randle PJ, Garland PB, Hales CN, News holme EA: The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789, 1963
33. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Pe- tersen KF, Shulman GI: Effects of free fatty acids on glucose transport and IRS-1-asso- ciated phosphatidylinositol 3-kinase activity. JClinInvest 103:253-259, 19995. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176, 2000
34. Neschen S, Morino K, Hammond LE, Zhang D, Liu ZX, Romanelli AJ, Cline GW, Pongratz RL, Zhang XM, Choi CS, Coleman RA, Shulman GI: Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn- 3-phosphate acyltransferase 1 knockout mice. Cell Metab 2:55-65, 2005
35. Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI: Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 275:8456-8460, 2000
36. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI: Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodys- trophy. J Clin Invest 109:1345-1350, 2002
37. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI: Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603-608, 2005
38. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, Cline GW, Be- froy D, Zemany L, Kahn BB, Papademetris X, Rothman DL, Shulman GI: The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad SciUSA 104:12587-12594, 2007
39. Perseghin G, Price TB, Petersen KF, Ro- den M, Cline GW, Gerow K, Rothman DL, Shulman GI: Increased glucose transport- phosphorylation and muscle glycogen synthesis after exercise training in insulin- resistant subjects. N Engl J Med 335:1357-1362, 1996
40. Kumar AF, Gruessner RW, Seaquist ER: Risk of glucose intolerance and diabetes in hemipancreatectomized donors selected for normal preoperative glucose metabolism. Diabetes Care 31:1639-1643, 2008
41. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Be- lisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Pshezhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P: A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881-885, 2007
42. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson Bostrom K, Isomaa B, Lettre G, Lindblad U, Lyon HN, Melander O, New- ton-Cheh C, Nilsson P, Orho-Melander M, Rastam L, Speliotes EK, Taskinen MR, Tuomi T, Guiducci C, Berglund A, Carlson J, Gianniny L, Hackett R, Hall L, HolmkvistJ, Laurila E, Sjogren M, Sterner M, Surti A, Svensson M, Svensson M, Te- whey R, Blumenstiel B, Parkin M, Defelice M, Barry R, Brodeur W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen K, Gates C, Sougnez C, Gage
43. D, Nizzari M, Gabriel SB, Chirn GW, Ma Q, Parikh H, Richardson D, Ricke D, Pur- cell S: Genome-wide association analysis identifies loci for type 2 diabetes and tri- glyceride levels. Science 316:1331-1336, 2007
44. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Wa- tanabe RM, Valle TT, Kinnunen L, Abeca- sis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M: A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341-1345, 2007
45. Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, Porte D Jr: Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42:222-229, 1976
46. Butler AE,JansonJ, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110, 2003
47. Garvey WT, OlefskyJM, Griffin J, Ham- man RF, Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222-234, 1985
48. Greenwood RH, Mahler RF, Hales CN: Improvement in insulin secretion in diabetes after diazoxide. Lancet 1:444-447,1976
49. Laedtke T, Kjems L, Porksen N, Schmitz O, Veldhuis J, Kao PC, Butler PC: Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am JPhysiol En- docrinol Metab 279:E520-E528, 2000
50. Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E: Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am JPhysiol En- docrinol Metab 292:E1775-E1781, 2007
51. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup- Poulsen T, Donath MY: Interleukin-1-re- ceptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517-26, 2007
52. Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B: Effects of subcutaneous gluca- gon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39: 1546-1553, 1996
53. Souza F, Simpson N, Raffo A, Saxena C, Maffei A, Hardy M, Kilbourn M, Goland R, Leibel R, MannJJ, Van Heertum R, Harris PE: Longitudinal noninvasive PET- based beta cell mass estimates in a spontaneous diabetes rat model. JClin ln- vest 116:1506-1513, 2006
54. Marselli L, Thorne J, Ahn YB, Omer A, Sgroi DC, Libermann T, Otu HH, Sharma A, Bonner-Weir S, Weir GC: Gene expression of purified beta-cell tissue obtained from human pancreas with laser capture microdissection. J Clin Endocrinol Metab 93:1046-1053, 2008
55. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R: Glucagon-like peptide 1 inhibits cell apopto- sis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149-5158, 2003
56. Soderberg S, Zimmet P, Tuomilehto J, de Courten M, Dowse GK, Chitson P, Sten- lund H, Gareeboo H, Alberti KG, Shaw J: High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius. J lntern Med 256:37-47, 2004
57. Bloomgarden ZT: American College of Endocrinology Pre-Diabetes Consensus Conference: part one. Diabetes Care 31:2062-2069, 2008